Abstract
Cystoid macular oedema (CMO), which is defined as a macular thickening and cystic changes due to accumulation of fluid, could be asymptomatic and only diagnosed using paraclinical techniques. Fluorescein angiography (FA) and optical coherence tomography (OCT) are useful in detecting CMO in clinical practice. Non-leaking CMO, also known as angiographically silent CMO, is referred to as cases of CMO without leakage in fluorescein angiography. This type of CMO has been reported in some retinal dystrophies, in cases of maculopathy as a side effect of certain drugs, and also in some systemic disorders. The exact mechanism and treatment options for this type of CMO are still not clear. This literature review aims to discuss different causes of non-leaking CMO, proposed mechanisms, and management options. Three sections including drugs, retinal dystrophies, and systemic disorders are discussed in this review.
摘要
黄斑囊样水肿 (CMO) 定义为液体蓄积造成的黄斑区增厚和囊样改变, 可能无症状, 并且只能由临床辅助检查所诊断。荧光血管造影 (FA) 和光学相干断层扫描 (OCT) 是临床上检测CMO的有效手段。无渗漏的CMO, 在造影中以“安静的CMO”著称, 特指那些在荧光素血管造影中没有荧光渗漏的CMO。在某些视网膜营养不良、药物副作用及全身性疾病中可见这种类型的CMO。该类型CMO的发病机制和治疗方法仍不明确。本综述旨在讨论造成无渗漏CMO的不同病因、潜在机制和管理方法。本综述讨论了药物、视网膜营养不良及系统性疾病三个部分。
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Holló G, Aung T, Cantor LB, Aihara M. Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management. Surv Ophthalmol. 2020;65:496–512.
Chetrit M, Bonnin S, Mané V, Erginay A, Tadayoni R, Gaudric A, et al. Acute pseudophakic cystoid macular edema imaged by optical coherence tomography angiography. Retina 2018;38:2073–80.
Bringmann A, Reichenbach A, Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res. 2004;36:241–9.
Lingao MD, Ganesh A, Karthikeyan AS, Al Zuhaibi S, Al-Hosni A, Al Khayat A, et al. Macular cystoid spaces in patients with retinal dystrophy. Ophthalmic Genet. 2016;37:377–83.
Mavrikakis E, Lam WC. Macular schisis and detachment secondary to large optic nerve head cup: a newly recognized syndrome amenable to vitrectomy. Acta ophthalmologica. 2011;89:95–6.
Gohil R, Sivaprasad S, Han L, Mathew R, Kiousis G, Yang Y. Myopic foveoschisis: a clinical review. Eye 2015;29:593–601.
Dajani HM, Lauer AK. Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol. 2006;41:197–200.
Domanico D, Carnevale C, Fragiotta S, Verboschi F, Altimari S, Vingolo EM. Cystoid macular edema induced by low doses of nicotinic Acid. Case reports in ophthalmological medicine. 2013;2013:713061.
Courtney R, Singh R. Spectral domain optical coherence tomography features in niacin maculopathy. Eye 2014;28:629–32.
Cai S, Liu TA, Arevalo JF. Evolution of ellipsoid zone abnormalities on optical coherence tomography associated with niacin maculopathy. JAMA Ophthalmol. 2019;137:849–51.
Freisberg L, Rolle TJ, Ip MS. Diffuse macular edema in niacin-induced maculopathy may resolve with dosage decrease. Retinal Cases Brief Rep. 2011;5:227–8.
Padrón Pérez N, Rubio Caso MJ, Arias Barquet L, Caminal, Mitjana JM. Bilateral cystoid macular edema in a patient with taxane-based chemotherapy. Can J Ophthalmol. 2013;48:e3–4.
Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci. 2003;80:277–9.
Arora S, Surakiatchanukul T, Arora T, Errera MH, Agrawal H, Lupidi M, et al. Retinal toxicities of systemic anticancer drugs. Surv Ophthalmol. 2022;67:97–148.
Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. European Journal of Ophthalmology. 2022;32:602–11.
Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol. 2012;32:299–304.
Shih CH, Lee YC. Impaired retinal pigment epithelium in paclitaxel-induced macular edema: a case report. Med (Baltim). 2018;97:e11229.
Nomi N, Ota M, Fukumura M, Nuno Y, Hatano M, Wakuta M, et al. Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy. Jpn J Ophthalmol. 2018;62:163–7.
Lee J, Ra H, Baek J. Ultra-widefield angiographic imaging of albumin-bound paclitaxel-induced cystoid macular edema. Indian J Ophthalmol. 2019;67:2058–9.
Nakao S, Ikeda Y, Emi Y, Ishibashi T. Possibility of Müller cell dysfunction as the pathogenesis of paclitaxel maculopathy. ophthalmic surg lasers imaging. Retina 2016;47:81–4.
Perez JM, Teo K, Ong R, Maruyama-Inoue M, Freund KB, Tan ACS. Optical coherence tomography characteristics of taxane-induced macular edema and other multimodal imaging findings. Graefes Arch Clin Exp Ophthalmol. 2020;258:1607–15.
Kaya M, Atas F, Gulsum Guc Z, Oztop I, Durak I, Saatci AO. A cross-sectional optical coherence tomography study in patients on taxane-based therapy and a case report with the literature review. Cutan Ocul Toxicol. 2020;39:287–93.
Chelala E, Arej N, Antoun J, Kourie HR, Zaarour K, Haddad FG, et al. Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients. Chemotherapy 2017;62:199–204.
Torrado LA, Fivgas GD. Unilateral cystoid macular edema and bilateral subfoveal hyperreflectivity following docetaxel chemotherapy: A case report. Am J Ophthalmol Case Rep. 2020;20:100995.
Haider A, Bababeygy SR, Lu SY. Cystoid macular edema and macular pigmentation associated with nab-Paclitaxel therapy. Retin Cases Brief Rep. 2015;9:220–2.
Nghiem-Buffet S, Cohen SY, Giocanti-Auregan A. Docetaxel retinopathy: a case report. Case Rep. Ophthalmol. 2017;8:21–5.
Elhusseiny AM, Relhan N, Smiddy WE. Docetaxel-induced maculopathy possibly potentiated by concurrent hydroxychloroquine use. Am J Ophthalmol Case Rep. 2019;16:100560.
Enzsoly A, Kammerer K, Nemeth J, Schneider M. Bilateral cystoid macular edema following docetaxel chemotherapy in a patient with retinitis pigmentosa: a case report. BMC Ophthalmol. 2015;15:32.
Ehlers J, Rayess H, Steinle N. Topical dorzolamide therapy for taxane-related macular oedema. Eye 2013;27:102–4.
Dwivedi R, Tiroumal S. Possible efficacy of topical dorzolamide in the treatment of paclitaxel-related cystoid macular edema. Retin Cases Brief Rep. 2018;12:75–9.
Yokoe T, Fukada I, Kobayashi K, Shibayama T, Miyagi Y, Yoshida A, et al. Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review. Case Rep. Oncol. 2017;10:605–12.
Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol. 2007;22:151–3.
Koo NK, Kim YC. A case of paclitaxel-induced maculopathy treated with methazolamide. Korean J Ophthalmol. 2012;26:394–7.
Meyer KM, Klink T, Ugurel S, Bröcker EB. Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol. 2012;250:463–4.
Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom. 2012;95:233–6.
Rahman HT, Yeh S, Bergstrom CS. Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab. J Ocul Pharm Ther. 2013;29:360–2.
Hassall MM, Andrew NH. Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema. BMJ Case Rep. 2016;2016:https://doi.org/10.1136/bcr-2015-212733.
Baskin DE, Garg SJ. Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab. Can J Ophthalmol. 2011;46:200–1.
Matsuoka N, Hasebe H, Mayama T, Fukuchi T. Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane). Case Rep. Ophthalmol Med. 2015;2015:181269.
Burgos-Blasco B, Hernandez-Ruiz S, Lopez-Guajardo L, Donate-Lopez J. Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy. Am J Ophthalmol Case Rep. 2020;18:100653.
Murphy CG, Walsh JB, Hudis CA, Lake D, Theodoulou M. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol. 2010;28:e684–7.
Tapia Quijada HE, Quijada Fumero E, Mesa Lugo FI, Serrano García M, Betancor Caro N. Nepafenac for cystoid macular oedema secondary to paclitaxel. Arch Soc Esp Oftalmol (Engl Ed). 2021;96:434–7.
Hanif AM, Armenti ST, Taylor SC, Shah RA, Igelman AD, Jayasundera KT, et al. Phenotypic spectrum of pentosan polysulfate sodium-associated maculopathy: a multicenter study. JAMA Ophthalmol. 2019;137:1275–82.
De Larochellière E, Bourgault S. Pentosan polysulfate sodium-induced pigmentary maculopathy with nonleaking cystoid macular edema successfully treated with anti–vascular endothelial growth factor therapy. Retinal Cases & Brief Reports. 2022;16:482–5.
Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol. 2014;98:200–6.
Hong EH, Ahn SJ, Lim HW, Lee BR. The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. BMC Ophthalmol. 2017;17:124.
Parikh VS, Modi YS, Au A, Ehlers JP, Srivastava SK, Schachat AP, et al. Nonleaking cystoid macular edema as a presentation of hydroxychloroquine retinal toxicity. Ophthalmology 2016;123:664–6.
Chang CY, Sheu SJ. Macular edema might be a rare presentation of hydroxychloroquine-induced retinal toxicity. Taiwan J Ophthalmol. 2017;7:56–8.
Kim DG, Yoon CK, Kim HW, Lee SJ. Effect of topical dorzolamide therapy on cystoid macular edema in hydroxychloroquine retinopathy. Can J Ophthalmol. 2018;53:e103–e7.
Ali S, Seth R. X-linked juvenile retinoschisis in females and response to carbonic anhydrase inhibitors: case report and review of the literature. Semin Ophthalmol. 2013;28:50–4.
Wang NK, Liu L, Chen HM, Tsai S, Chang TC, Tsai TH, et al. Clinical presentations of X-linked retinoschisis in Taiwanese patients confirmed with genetic sequencing. Mol Vis. 2015;21:487–501.
Önen M, Zor K, Küçük E, Yıldırım G. X-linked retinoschisis in females in a consanguineous family: a rare entity. Turk J Ophthalmol. 2020;50:252–4.
Guimaraes TAC, Capasso JE, Levin AV. Paradoxical response to carbonic anhydrase inhibitors in patients with intraretinal cystoid spaces. Ophthalmic Genet. 2019;40:213–8.
Ghajarnia M, Gorin MB. Acetazolamide in the treatment of X-linked retinoschisis maculopathy. Arch Ophthalmol. 2007;125:571–3.
Khandhadia S, Trump D, Menon G, Lotery AJ. X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype. Eye (Lond). 2011;25:922–8.
Verbakel SK, van de Ven JP, Le Blanc LM, Groenewoud JM, de Jong EK, Klevering BJ, et al. Carbonic anhydrase inhibitors for the treatment of cystic macular lesions in children with X-linked juvenile retinoschisis. Invest Ophthalmol Vis Sci. 2016;57:5143–7.
Galantuomo MS, Fossarello M, Cuccu A, Farci R, Preising MN, Lorenz B, et al. Rebound macular edema following oral acetazolamide therapy for juvenile X-linked retinoschisis in an Italian family. Clin Ophthalmol. 2016;10:2377–82.
Ansari WH, Browne AW, Singh RP. Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids. Am J Ophthalmol Case Rep. 2017;5:48–51.
Bechet L, Atia R, Zeitz C, Mohand-Saïd S, Sahel JA, Barale PO, et al. Management of a case of Enhanced S-cone syndrome with massive foveoschisis treated with pars plana vitrectomy with silicone oil tamponade. Ophthalmic Genetics. 2021;42:615–8.
Kiszkielis M, Lubiński W, Penkala K. Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient. Doc Ophthalmologica. 2013;126:241–6.
Audo I, Michaelides M, Robson AG, Hawlina M, Vaclavik V, Sandbach JM, et al. Phenotypic variation in enhanced S-cone syndrome. Invest Ophthalmol Vis Sci. 2008;49:2082–93.
Iannaccone A, Fung KH, Eyestone ME, Stone EM. Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide. Am J Ophthalmol. 2009;147:307–12. e2
Genead MA, Fishman GA, McAnany JJ. Efficacy of topical dorzolamide for treatment of cystic macular lesions in a patient with enhanced S-cone syndrome. Doc ophthalmologica. 2010;121:231–40.
Bušić M, Bjeloš M, Bosnar D, Ramić S, Bušić I. Cystoid macular lesions are resistant to topical dorzolamide treatment in enhanced S-cone syndrome child. Doc Ophthalmologica. 2016;132:67–73.
Salvatore S, Fishman GA, Genead MA. Treatment of cystic macular lesions in hereditary retinal dystrophies. Surv Ophthalmol. 2013;58:560–84.
Ganesh A, Stroh E, Manayath GJ, Al-Zuhaibi S, Levin AV. Macular cysts in retinal dystrophy. Curr Opin Ophthalmol. 2011;22:332–9.
Iovino C, Au A, Hilely A, Violanti S, Peiretti E, Gorin MB, et al. Evaluation of the choroid in eyes with retinitis pigmentosa and cystoid macular edema. Invest Ophthalmol Vis Sci. 2019;60:5000–6.
Lai YH, Capasso JE, Kaiser R, Levin AV. Intraretinal cystoid spaces in a patient with retinitis pigmentosa due to mutation in the MAK gene. Ophthalmic Genet. 2016;37:424–6.
Yeo JH, Kim YJ, Yoon YH. Optical coherence tomography angiography in patients with retinitis pigmentosa–associated cystoid macular edema. Retina 2020;40:2385–95.
Liew G, Moore AT, Webster AR, Michaelides M. Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2015;56:1531–6.
Mansour AM, Elnahry AG, Tripathy K, Foster RE, Mehanna CJ, Vishal R, et al. Analysis of optical coherence angiography in cystoid macular oedema associated with gyrate atrophy. Eye (Lond). 2021;35:1766–74.
Zhioua Braham I, Ammous I, Maalej R, Boukari M, Mili Boussen I, Errais K, et al. Multimodal imaging of foveoschisis and macular pseudohole associated with gyrate atrophy: a family report. BMC Ophthalmol. 2018;18:89.
Tripathy K, Chawla R, Sharma YR, Gogia V. Ultrawide field fluorescein angiogram in a family with gyrate atrophy and foveoschisis. Oman J Ophthalmol. 2016;9:104–6.
Kim SJ, Lim DH, Kim JH, Kang SW. Gyrate atrophy of the choroid and retina diagnosed by ornithine-δ-aminotransferase gene analysis: a case report. Korean J Ophthalmol. 2013;27:388–91.
Çavdarlı C, Şahlı E, Çavdarlı B, Alp MN. Regression of macular edema with topical brinzolamide and nepafenac alone and identification of a novel gyrate atrophy mutation. Arquivos Brasileiros de Oftalmologia. 2020;83:149–52.
Piozzi E, Alessi S, Santambrogio S, Cillino G, Mazza M, Iggui A, et al. Carbonic anhydrase inhibitor with topical NSAID therapy to manage cystoid macular edema in a case of gyrate atrophy. Eur J Ophthalmol. 2017;27:e179–e83.
Alparslan Ş, Fatih MT, Muhammed Ş, Adnan Y. Cystoid macular edema secondary to gyrate atrophy in a child treated with sub-tenon injection of triamcinolone acetonide. Rom J Ophthalmol. 2018;62:246.
Elnahry AG, Hassan FK, Abdel-Kader AA. Bevacizumab for the treatment of intraretinal cystic spaces in a patient with gyrate atrophy of the choroid and retina. Ophthalmic Genet. 2018;39:759–62.
Elnahry AG, Aboulfotouh MR, Nassar GA. Treatment of intraretinal cystic spaces associated with gyrate atrophy of the choroid and retina with intravitreal bevacizumab. J Pediatr Ophthalmol Strabismus. 2020;57:400–6.
Casalino G, Pierro L, Manitto MP, Michaelides M, Bandello F. Resolution of cystoid macular edema following arginine-restricted diet and vitamin B6 supplementation in a case of gyrate atrophy. J aapos. 2018;22:321–3.
Heller D, Weiner C, Nasie I, Anikster Y, Landau Y, Koren T, et al. Reversal of cystoid macular edema in gyrate atrophy patients. Ophthalmic Genet. 2017;38:549–54.
Doguizi S, Sekeroglu MA, Anayol MA, Yilmazbas P. Arginine-restricted therapy resistant bilateral macular edema associated with gyrate atrophy. Case Rep. Ophthalmol Med. 2015;2015:137270.
Genead MA, Fishman GA. Cystic macular oedema on spectral-domain optical coherence tomography in choroideremia patients without cystic changes on fundus examination. Eye (Lond). 2011;25:84–90.
Murro V, Mucciolo DP, Giorgio D, Sodi A, Passerini I, Bacci G, et al. Optical coherence tomography (OCT) features of cystoid spaces in choroideremia (CHM). Graefes Arch Clin Exp Ophthalmol. 2019;257:2655–63.
Iovino C, Di Iorio V, Testa F, Bombace V, Melillo P, Vupparaboina KK, et al. Choroidal vascularity features in patients with choroideremia and cystoid spaces. Diagnostics. 2021;11:382.
Genead MA, McAnany JJ, Fishman GA. Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia. Retina 2012;32:826–33.
Beck KD, Wong RW, Gibson JB, Harper CA III. Nonleaking cystoid macular edema in Cohen syndrome. J Am Assoc Pediatr Ophthalmol Strabismus. 2019;23:38–9. e1
Liles CA, Tensmeyer MS, York JM, Ekanayake LS, Lew J. Cystoid macular edema in a 10-year-old boy with Cohen syndrome. Cureus. 2020;12:e8443.
Gabrielle P-H, Faivre L, Audo I, Zanlonghi X, Dollfus H, Thiadens AA, et al. Cystoid maculopathy is a frequent feature of Cohen syndrome-associated retinopathy. Sci Rep. 2021;11:1–12.
Rakusiewicz K, Kanigowska K, Hautz W, Wicher D, Młynek M, Wyszyńska M, et al. Coexistence of bilateral macular edema and pale optic disc in the patient with Cohen syndrome. Open. Medicine 2021;16:156–60.
Sevik MO, Aykut A, Şahin Ö. Resolution of cystoid macular edema with topical carbonic anhydrase inhibitor in a patient with retinal dystrophy associated with Cohen syndrome. Ophthalmic Genetics. 2021;42:619–23.
Nasser F, Kurtenbach A, Biskup S, Weidensee S, Kohl S, Zrenner E. Ophthalmic features of retinitis pigmentosa in Cohen syndrome caused by pathogenic variants in the VPS13B gene. Acta Ophthalmol. 2020;98:e316–e21.
Marco-Campmany A, Pacheco-Cervera J, Navarrete-Sanchis J, Tomás-Torrent JM, García-Canet S, Cuadrado-Gómez T, et al. Intravitreal bevacizumab in cystoid macular edema associated to maternally inherited diabetes and deafness’s macular dystrophy. European Journal of Ophthalmology. 2022;32:NP34–9.
Qian CX, Branham K, Khan N, Lundy SK, Heckenlively JR, Jayasundera T. Cystoid macular changes on optical coherence tomography in a patient with maternally inherited diabetes and deafness (MIDD)-associated macular dystrophy. Ophthalmic Genet. 2017;38:467–72.
Rao K, Murthy H, Muralidhar NS, Rani PK. Multiple myeloma masquerading as diabetic macular oedema. Case Reports. 2018;2018:bcr-2017.
da Cruz NFS, Milhomens Filho JAP, Ferraro DMN, Polizelli MU, de Moraes Ambrogini NSB. Hyperviscosity retinopathy and immunogammopathy maculopahy as new onset of multiple myeloma. Case Rep Ophthalmol. 2021;12:578–84.
Georgakopoulos CD, Plotas P, Angelakis A, Kagkelaris K, Tzouvara E, Makri OE. Dexamethasone implant for immunogammopathy maculopathy associated with IgA multiple myeloma. Ther Adv Ophthalmol. 2019;11:2515841418820441.
Reddy SV, Payne S, Schaal S. Angiographically silent macular edema. JAMA Ophthalmol. 2016;134:453–4.
Baker PS, Garg SJ, Fineman MS, Chiang A, Alshareef RA, Belmont J, et al. Serous macular detachment in Waldenström macroglobulinemia: a report of four cases. Am J Ophthalmol. 2013;155:448–55.
Besirli CG, Johnson MW. Immunogammopathy maculopathy associated with Waldenström macroglobulinemia is refractory to conventional interventions for macular edema. Retin Cases Brief Rep. 2013;7:319–24.
Author information
Authors and Affiliations
Contributions
MN: 1. Design of the work. 2. Data collection. 3. Drafting the article. 4. Critical revision of the article. 5. Final approval of the last version. SH:. 1. Data collection. 2. Drafting the article. 3. Critical revision of the article. 4. Final approval of the last version. SC: 1. Design of the work. 2. Drafting the article. 3. Critical revision of the article. 4. Final approval of the last version. AG: 1. Design of the work. 2. Drafting the article. 3. Critical revision of the article. 4. Final approval of the last version. LM:. 1. Data collection. 2. Drafting the article. 3. Critical revision of the article. 4. Final approval of the last version. FA: 1. Design of the work. 2. Data collection. 3. Drafting the article. 4. Critical revision of the article. 5. Final approval of the last version
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Naseripour, M., Hemmati, S., Chaibakhsh, S. et al. Cystoid macular oedema without leakage in fluorescein angiography: a literature review. Eye 37, 1519–1526 (2023). https://doi.org/10.1038/s41433-022-02230-z
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-022-02230-z
